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Although antibodies specific for a variety of haptens have been obtained following the classic technique of Landsteiner,2 no record has been found of the use of cardiac glycosides for such studies. Digitalis-specific antibodies could conceivably be an extremely useful tool (1) in the immunological assay of digitalis in plasma and tissue fluids, (2) in the therapy of severe digitalis toxicity, and (3) in the study of the mechanism of action of digitalis. This report describes the coupling of the cardiac glycoside, digoxin,3 to bovine serum albumin and the use of the resulting conjugate as an antigen to induce the formation of antibodies which exhibit digoxin specificity.
Materials and Methods.-Reagents: Bovine serum albumin (BSA) was obtained as fraction V powder from Pentex, Inc. "Lanoxin"-brand digoxin and tritiated digoxin (Dig-H3; 112.6 ,.c/ mg; 1 mg/ml in 95% ethanol) were generously supplied by Burroughs Wellcome and Company. Cortisone-1,2-H3 (5.83 mc/mg), hydrocortisone-1,2-H3(50.2 mC/mg), dehydroepiandrosterone7ac-H3 (5.62 mc/mg), and dehydroepiandrosterone-7a-H3 sulfate, ammonium salt (4.23 mc/mg) were obtained from the New England Nuclear Corporation and were chromatographically purified by Dr. William Drucker and then dissolved in absolute methanol. Isotopic compounds were diluted with buffer for use in dialysis experiments.
Preparation of protein-digoxin conjugates: Digoxin (Dig) which consists of a steroidal aglycone linked to three digitoxose residues (see Fig. 2 ) was conjugated to BSA by a periodate oxidation method suggested by Dr. Bernard Erlanger, Columbia University, and based on a technique originally described by Erlanger and Beiser4 5 for other hapten-protein conjugates. One BSA-Dig conjugate was prepared as follows: To 218.8 mg (0.28 mmole) digoxin were added 30 ml 0.1 M sodium periodate, 40 ml absolute ethanol, and 10 ml dioxane. After 30 min at room temperature, 1.8 ml 1 M ethylene glycol was added and the entire reaction mixture was added to 280 mg BSA in 10 ml water which had been adjusted to pH 9.3 with 5% K2CO3. The mixture was stirred for 1 hr at room temperature with dropwise addition of 5% K2CO3 to maintain the pH in the 9.0-9.5 range. After 1 hr, 150 mg sodium borohydride was added and the reaction mixture was set aside for 24 hr at room temperature. Approximately 5.4 ml 1 M formic acid was added to lower the pH to 5.5; at about pH 5.8, considerable precipitation occurred. After 1 hr at room temperature, 1.5 ml 1 M NH40H was added to raise the pH to 8.5. Some cloudiness persisted and the mixture was dialyzed overnight against running tap water. The pH was lowered to 4.8 by the dropwise addition of 1.85 ml 0.1 N HCl with considerable precipitation of protein. After 4 hr at 40C, the suspension was centrifuged 1 hr at 1800 rpm at 40C. The precipitate was partially redissolved in 0.15 M NaHCO3, dialyzed for 5 days against running tap water, lyophilized, and stored as a greenish-white powder. When examined spectrophotometrically in 83% H2SO4,6 this BSA-Dig preparation had absorption maxima at 388 and 465 mA, respectively, which were absent in unconjugated BSA. These absorption maxima appeared to be related to absorption maxima of digoxin at 388 and 480 mu, respectively, under comparable conditions. On the assumption that the difference between the molar extinction coefficients of BSA and BSA-Dig at 465 m;u was due to the presence of digoxin in the conjugate, a rough estimate was made that 2.7 digoxin residues were conjugated to each mole of BSA; an estimate of 1.4 digoxin residues per mole of BSA was made using the extinction coefficients at 388 m;u. Hydrolysis of the conjugate and precise analytical studies will be required to obtain an exact value (conjugates recently prepared by a 71 slightly modified method have had extinction coefficients at these wavelengths consistent with the presence of five digoxin residues per mole of albumin, but these preparations have not yet been studied immunologically).
Immunological procedures: After control preimmunization sera had been obtained, rabbits were immunized by the injection of BSA-Dig, 1 mg/ml in complete Freund's adjuvant, three injections of 0.4 ml in the toe pads over a 4-week period. 'Most animals received a single booster injection intramuscularly. Mlost antisera reported herein represent a pooled series of terminal bleedings obtained from individual animals about 10 weeks later. Control antisera were obtained by immunizing in a similar manner with BSA, human serum albumin (HSA), human gamma globulin (HGG), whole human serum (WHS), hen's egg albumin (HEA), purin-6-oyl-BSA (Pur-BSA),7 purin-6-oyl-HSA (Pur-HSA),7 glucosyl-phenylazo-BSA (Glu-BSA),8 and galactosylphenylazo-BSA (Gal-BSA).8
Equilibrium dialysis studies9' 10 were carried out at 4VC in isotonic Tris-buffered saline, pH 7.5.11 Antiserum, gamma globulin, or buffer was added to Visking dialysis tubing together with radioactive digoxin or steroid. The bag was tied and allowed to dialyze against an equal volume (5-10 ml) of buffer in a screw-capped test tube with frequent mixing (in recent experiments, a mechanical shaker has been used); after 5 days, 0.5-1.0-ml aliquots were removed for counting of radioactivity in 7.5-20 ml (usually 15 ml) of a scintillation mixture containing 6 gm 2,5-diphenyloxazole, 375 mg 1,4-bis-[2-(4-methyl-5-phenyloxazolyl)]-benzene, and 100 gm naphthalene in 1 liter dioxane. Measurements of radioactivity were carried out in a Packard Tri-Carb scintillation counter. Good agreement between final results was observed when the isotope was placed inside and outside the dialysis bag at the start of an experiment, but recoveries of added radioactivity were more satisfactory when isotope was added outside the dialysis bag. The efficiency of counting was excellent in buffer solution, -y-globulin solutions, and most control rabbit sera, but it was impaired in most anti-BSA-Dig sera, particularly in high concentration. Since no significant binding of radioactivity to dialysis tubing or glassware was observed, the amount of radioactivity inside any dialysis bag containing anti-BSA-Dig serum (or a 1:5 dilution of control rabbit serum) was calculated by subtracting the amount of radioactivity observed outside the dialysis bag from the total amount recovered in buffer control tubes. The amount of protein-bound radioactivity was calculated by subtracting the observed amount of free radioactivity outside the dialysis bag and the calculated amount inside from the total amount of radioactivity recovered. No significant volume change inside or outside dialysis tubing was noted during these experiments.
For inhibition studies, nonradioactive digoxin and other compounds were dissolved in 95%7c ethanol prior to dilution with buffered saline; the final concentrations of ethanol in the reaction mixture did not inhibit the binding of tritiated digoxin by anti-BSA-Dig sera.
-y-Globulin fractions of rabbit sera were prepared chromatographically by isolation of the first 280-mit absorbing peak obtained from DEAE cellulose'2 in 0.01 M pH 7.5 phosphate containing 0.015 ll saline.'3 In seven of nine preparations, a single -y-globulin arc was seen in immunoelectrophoresis with goat or sheep anti-whole rabbit serum; an additional p3-globulin component was detected in the preparations from sera BSA-2 and DB-16X. 
One ml Dig-Hs (0.45 pc/ml) and 2 ml serum, diluted with buffer to final volume of 10 ml, were placed in dialysis tubing and dialyzed against equal volume of buffer at 40C. Equal concentrations of radioactivity were found inside and outside dialysis tubing in buffer control in which Dig-Hz had initially been placed outside tubing.
* Preimmunization serum from rabbit DB-2 was severely hemolyzed.
antigens (Table 2 ). The digoxin-binding capacity of anti-BSA-Dig serum DB-9 was not removed by prior absorption with BSA but was substantially diminished after absorption with BSA-Dig.14 Chromatographically separated y-globulin from anti-BSA-Dig sera possessed strong Dig-H3 binding capacity, while y-globulins from normal rabbit sera and from rabbit antisera to other antigens lacked this capacity (Tables 3 and 4) . Nonradioactive digoxin was, as expected, a very potent inhibitor of the binding of Dig-H3 by anti-BSA-Dig sera. In Figure 1 is plotted the inhibition observed anti-BSA-Dig serum DB-6 (1:640 dilution). The 3067 cts/10 min/0.5 ml outside the dialysis bag in the buffer control was used as a theoretical 100% inhibition value; 541 cts/ 10 min/0.5 ml outside the bag in the presence of antibody and in the absence of nonradioactive digoxin as an inhibitor was used as a 0% inhibition value. when increasing amounts of nonradioactive digoxin were added to a constant amount of anti-BSA-Dig serum and tritiated digoxin. The inhibitory capacity of digoxin was compared with that of digitoxin which lacks the C12 hydroxyl group of digoxin,'8 but is otherwise chemically identical. Digitoxin has some inhibitory capacity, but, on a molar basis, digoxin is about ten times as effective in producing 50 per cent inhibition of the reaction between Dig-H3 and anti-BSA-Dig serum DB-6 (Table 5) . Under similar conditions, oubain, a more distantly related cardiac glycoside, exerted slight inhibition. Cortisone, corticosterone, and cholesterol also appeared to possess minimal inhibitory activity (Table 5 ), but it was not possible to be certain that this inhibition was significant. The cross-reactivity of antidigoxin antibodies was conclusively demonstrated by showing that y-globulin from anti-BSA-Dig sera, but not from various control sera, possessed a significant capacity to bind tritiated cortisone, hydrocortisone, dehydroepiandrosterone, and dehydroepiandrosterone sulfate (Table 4) Discussion. -The digoxin-containing antigen used in these studies was effective in eliciting digoxin-specific antibodies but the nature of the binding of digoxin to protein has not yet been chemically defined. The terminal digitoxose of digoxin (Fig. 2) Figure 2 is slightly modified'9 from that proposed by Erlanger and Beiser4 for the conjugation of periodate-sensitive ribose derivatives to protein. In the case of digoxin, however, the lactone ring of the aglycone conceivably could react also with free amino groups under the alkaline conditions employed; this and other possible reaction mechanisms cannot be ruled out until hydrolysis of the digoxin-protein conjugate and chemical identification of the hydrolytic products have been performed.
Definitive evidence for the presence of digoxin-specific antibodies in most anti-BSA-Dig sera was obtained in equilibrium dialysis experiments. It is clear from the data presented in Table 1 that anti-BSA-Dig sera possess a potent digoxin-binding capacity; this capacity was not present in preimmunization sera and, as seen in Table 3 , it was a property of the -y-globulin fraction of anti-BSA-Dig sera. It was not a nonspecific result of immunization because antisera to BSA or other antigens and -y-globulin fractions derived from these antisera lacked this digoxinbinding capacity (Tables 2-4 ). The digoxin-specificity of these antisera was further confirmed by the demonstrations that digoxin is a potent inhibitor of the binding of tritiated digoxin by anti-BSA-Dig serum (Fig. 1) and that, on a molar basis, digoxin is a far more effective inhibitor of this binding than the other cardiac glycosides and steroids studied (Table 5) . Like antibodies to steroid haptens,20-23 digoxin-specific antibodies cross-react with other steroids. The cross-reactivity with digitoxin was anticipated in view of its close chemical similarity to digoxin, and the cross-reaction was readily apparent in inhibition experiments ( Table 5) . The cross-reactivity with steroids was not conclusively demonstrated in these experiments but was apparent (Table 4) when the binding of tritiated steroid hormones to relatively large amounts of -y-globulin from anti-BSA-Dig sera was directly demonstrated.
This communication contains the first known description of the experimental production of antibodies with specificity for cardiac glycosides. Recently, the undiluted sera of two digitoxin-treated patients (one with digitoxin-induced thrombocytopenic purpura, the other with increased dosage requirements) were found to contain 10-18 per cent of a given amount of added digitoxin-H3 in electrophoretically separated e-globulin fractions, whereas normal sera contained 4-7 per cent in their -y-globulins after similar starch gel electrophoresis.24 This digitoxin-binding capacity, while clinically important, is too weak to be of practical value in the studies for which the antibodies described in the current report were prepared.
It is hoped that the ability of digoxin to inhibit the binding of tritiated digoxin (Fig. 1) Digoxin-specific antibodies may also be useful in the study of the mechanism of action of digoxin on the myocardium and on renal tubular epithelium. Several workers have demonstrated tritiated digoxin in the A-band of cardiac myofibrils by electron microscopy,3-33 but physiological studies of cation flux34 suggest that a more important site of action may be at the membrane level. The rapid disappearance of digoxin action following addition of antibody to a medium containing muscle cells might lend support to the hypothesis that the observed action of digoxin at the cell membrane level is more important pharmacologically than its apparent anatomical localization in the myofibril. Such studies have been initiated recently.
Summary. -Rabbits immunized with a synthetic protein-digoxin conjugate formed antibodies capable of specific binding of tritiated digoxin. Nonradioactive digoxin inhibited the binding of tritiated digoxin by antidigoxin antibody, and this inhibitory capacity of nonradioactive digoxin may prove useful in the development of an immunological assay for digoxin in plasma and biological fluids. The possible value of digoxin-specific antibodies in the treatment of experimental digoxin toxicity and in the study of mechanism of digoxin action has been discussed.
We are indebted to Dr. B. F. Erlanger, Columbia University, who suggested the conjugation method; to Dr. S. Bloomfield, Burroughs Wellcome and Company, who generously provided the nonradioactive and tritiated digoxin; and to Dr. W. Drucker, New York University School of Medicine, who purified the other tritiated steroids. Drs. C. Ragan, A. M. Briscoe, and S. MI.
Beiser gave helpful suggestions, and Miss Diane Lepore and Miss Ann Wargo provided superb technical assistance.
